These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 20539838)
1. Optimal use of beta-blockers in high-risk hypertension: a guide to dosing equivalence. McGill JB Vasc Health Risk Manag; 2010 Jun; 6():363-72. PubMed ID: 20539838 [TBL] [Abstract][Full Text] [Related]
2. Blood pressure lowering efficacy of dual alpha and beta blockers for primary hypertension. Wong GW; Laugerotte A; Wright JM Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD007449. PubMed ID: 26306578 [TBL] [Abstract][Full Text] [Related]
3. The Role of Beta-Blockers in the Treatment of Hypertension. Cruickshank JM Adv Exp Med Biol; 2017; 956():149-166. PubMed ID: 27957711 [TBL] [Abstract][Full Text] [Related]
4. Using fixed-dose combination therapies to achieve blood pressure goals. Chrysant SG Clin Drug Investig; 2008; 28(11):713-34. PubMed ID: 18840014 [TBL] [Abstract][Full Text] [Related]
6. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Dahlöf B; Sever PS; Poulter NR; Wedel H; Beevers DG; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J; Lancet; 2005 Sep 10-16; 366(9489):895-906. PubMed ID: 16154016 [TBL] [Abstract][Full Text] [Related]
7. Continuous-Infusion Labetalol vs Nicardipine for Hypertension Management in Stroke Patients. Hecht JP; Richards PG J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):460-465. PubMed ID: 29092768 [TBL] [Abstract][Full Text] [Related]
8. β-blockers: a review of their pharmacological and physiological diversity in hypertension. Ripley TL; Saseen JJ Ann Pharmacother; 2014 Jun; 48(6):723-33. PubMed ID: 24687542 [TBL] [Abstract][Full Text] [Related]
9. Insights on β-blockers for the treatment of hypertension: A survey of health care practitioners. Egan B; Flack J; Patel M; Lombera S J Clin Hypertens (Greenwich); 2018 Oct; 20(10):1464-1472. PubMed ID: 30289609 [TBL] [Abstract][Full Text] [Related]
10. Should β blockers no longer be considered first-line therapy for the treatment of essential hypertension without comorbidities? Elliott WJ; Childers WK Curr Cardiol Rep; 2011 Dec; 13(6):507-16. PubMed ID: 21898116 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis. Van Bortel LM; Fici F; Mascagni F Am J Cardiovasc Drugs; 2008; 8(1):35-44. PubMed ID: 18303936 [TBL] [Abstract][Full Text] [Related]
12. Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction. Frishman WH; Henderson LS; Lukas MA Vasc Health Risk Manag; 2008; 4(6):1387-400. PubMed ID: 19337551 [TBL] [Abstract][Full Text] [Related]
13. [Nebivolol, a third generation beta blocker: the modern treatment of hypertension. Results of a multicentric observational study]. von Fallois J; Faülhaber HD Fortschr Med Orig; 2000 Jul; 118 Suppl 2():77-82. PubMed ID: 15700490 [TBL] [Abstract][Full Text] [Related]
14. Implication of different initial beta blockers on treatment persistence: atenolol vs new-generation beta blocker, a population-based study. Choi YJ; Ah YM; Kong J; Choi KH; Kim B; Han N; Yu YM; Oh JM; Shin WG; Lee HY; Lee JY Cardiovasc Ther; 2016 Aug; 34(4):268-75. PubMed ID: 27214564 [TBL] [Abstract][Full Text] [Related]
15. Effects of third-generation β-blockers, atenolol or amlodipine on blood pressure variability and target organ damage in spontaneously hypertensive rats. Del Mauro JS; Prince PD; Allo MA; Santander Plantamura Y; Morettón MA; González GE; Bertera FM; Carranza A; Gorzalczany SB; Chiappetta DA; Morales C; Gelpi RJ; Taira CA; Polizio AH; Donato M; Höcht C J Hypertens; 2020 Mar; 38(3):536-545. PubMed ID: 32028517 [TBL] [Abstract][Full Text] [Related]
17. Combining other antihypertensive drugs with β-blockers in hypertension: a focus on safety and tolerability. Richards TR; Tobe SW Can J Cardiol; 2014 May; 30(5 Suppl):S42-6. PubMed ID: 24518661 [TBL] [Abstract][Full Text] [Related]
18. Antihypertensive treatment with beta-blockers in the metabolic syndrome: a review. Carella AM; Antonucci G; Conte M; Di Pumpo M; Giancola A; Antonucci E Curr Diabetes Rev; 2010 Jul; 6(4):215-21. PubMed ID: 20459394 [TBL] [Abstract][Full Text] [Related]
19. Vasodilating versus first-generation β-blockers for cardiovascular protection. Fares H; Lavie CJ; Ventura HO Postgrad Med; 2012 Mar; 124(2):7-15. PubMed ID: 22437211 [TBL] [Abstract][Full Text] [Related]
20. Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes. Fogari R; Zoppi A; Lazzari P; Mugellini A; Lusardi P; Preti P; Van Nueten L; Vertommen C J Hum Hypertens; 1997 Nov; 11(11):753-7. PubMed ID: 9416986 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]